Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-03-22
2011-03-22
Gussow, Anne M. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S006120
Reexamination Certificate
active
07910314
ABSTRACT:
This invention provides methods for determining whether a breast, prostate or ovarian tumor or tumor cell is aggressive, based on the quantitative measurement of p66-Shc and phosphorylated Shc. This invention also provides related methods of determining the likelihood of tumor recurrence. This invention further provides a method for determining whether a tumor can be successfully treated using a tyrosine kinase inhibitor. Finally, this invention provides antibodies and kits for practicing the instant methods.
REFERENCES:
patent: 5912183 (1999-06-01), Comoglio et al.
patent: 6025145 (2000-02-01), Godowski et al.
patent: 6492138 (2002-12-01), McGlade et al.
patent: 6673914 (2004-01-01), Hoon
patent: 6777415 (2004-08-01), Daley et al.
patent: 7572886 (2009-08-01), Girard et al.
patent: 2004/0209809 (2004-10-01), Saucier et al.
patent: 2005/0004008 (2005-01-01), Frackelton et al.
patent: 2007/0060539 (2007-03-01), Frackelton, Jr. et al.
patent: 2008/0132462 (2008-06-01), Frackelton, Jr. et al.
patent: 2008/0299590 (2008-12-01), Frackelton, Jr. et al.
patent: 2009/0220965 (2009-09-01), Frackelton, Jr. et al.
patent: 2002-539789 (2002-11-01), None
patent: WO 00/56886 (2002-11-01), None
patent: WO 03/073821 (2003-09-01), None
patent: WO 2005/038005 (2005-04-01), None
patent: WO 2007/058965 (2007-05-01), None
Jackson JG et al. Clinical Cancer Research 6:1135-1139, 2000.
Xie Y. et al. Biochemical and Biophysical Research Communications 221: 140-145, 1996.
Comb MJ. The NEB Transcript 7(1): 1-4, Dec. 1995.
Mathew, A., Pandey, M., and Murthy, N.S. Survival analysis: caveats and pitfalls. 1999. European Journal of Surgical Oncology. vol. 25, pp. 321-329.
Ohno-Machado, L. Modeling medical prognosis: survival analysis techniques. 2001. Journal of Biomedical Informatics. vol. 34, pp. 428-439.
Definition of Stroma. American Association for Cancer Research, Glossary of Cancer Terms, 2006.
Harvey, J.M., Clark, G.M., Osborne, C.K., and Allred, D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. Journal of Clinical Oncology, 1999. vol. 17, pp. 1474-1481.
Ronnov-Jessen, L., Peterson, O.W., and Bissell, M.J. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiological Reviews, 1996. vol. 76, pp. 69-125.
Van'T Veer, L.J., Dai, H., Van De Vijver, M.J., He, Y.D., Hart, A.A.M, Mao, M., Peterse, H.L., Van Der Kooy, K., Marton, M.J., Witteveen, A.T., Schreiber, G.J., Kerkhoven, R.M., Roberts, C., Linsley, P.S., Bernards, R., and Friend, S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature, 2002. vol. 415, pp. 530-536.
Lee, Igawa, Chen, Bemmel, Lin, Lin, Johansson, Christman, and Lin. p66-Shc protein is upregulated by steroid hormones in hormone-sensitive cancer cells and in primary prostate carcinomas. International Journal of Cancer, 2004. vol. 108, pp. 672-678.
Veeramani, Igawa, Yuan, Lin, Lee, Lin, Johansson, and Lin. Expression of p66-Shc protein correlates with proliferation of human prostate cancer cells. Oncogene, 2005. vol. 24, pp. 7203-7212.
Xie and Hung. p66 isoform down-regulated and not required for HER-2
eu signaling pathway in human breast cancer cell lines with HER-2
eu overexpression. Biochemical and Biophysical Research Communications, 1996. vol. 221, pp. 140-145.
Gura T., “Systems for Identifying New Drugs are Often Faulty,”Science278: 1041-1042 (1997).
Jain, R.K., “Barriers to Drug Delivery in Solid Tumors,”Scientific American, pp. 58-65, (1994).
Kisielow, M. et al., “Isoform-Specific Knockdown and Expression of Adaptor Protein ShcA Using Small Interfering Rna,”Biochem J.363:1-5 (2002).
Le, S., et al., “c-Jun N-terminal Kinase Specifically Phosphorylates p66ShcA at Serine 36 in Response to Ultraviolet Irradiation, ”J. Biol. Chem.276(51):48332-48336 (2001).
MSNBC News Services, “Mixed Results on a New Cancer Drug,” pp. 1-4 Nov. 9, 2000.
Murayama, Y., “Growth-inhibitory Effects of Epidermal Growth Factor on Human Breast Cancer and Carcinoma of the Esophagus Transplanted Into Nude Mice, ”Ann. Surg.211(3):263-268 (1990).
Sato, K., et al., “Adaptor Protein Shc is an Isoform-Specific Direct Activator of the Tyrosine Kinase c-Src,”J Biol. Chem., 277(33):29568-29576 (2002).
U.S. Appl. No. 10/687,396, filed Oct. 15, 2003, Frackelton, et al. (Exhibit 1).
American Cancer Society, “Breast cancer facts & figures 2001-2002.”American Cancer Society Surveillance Research. (2001) (Exhibit 2).
Andrechek, E.R., et al., “Tyrosine kinase signaling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer.”Breast Cancer Res., 2(3):211-6. (2000)(Exhibit 3).
Batzer, A.G., et al., “Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor.”Mol. Cell. Biol., 14(8):5192-201. (1994) (Exhibit 4).
Baumann, C. A., et al., “CAP defines a second signaling pathway required for insulin-stimulated glucose transport.”Nature, 407(6801):202-7. (2000) (Exhibit 5).
Ben-Levy, R., et al., “A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway.”EMBO J., 13(14):3302-11. (1994) (Exhibit 6).
Berger, M.S., et al., “Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.”Cancer Research, 48(5):1238-43. (1988) (Exhibit 7).
Besson, A., et al., “PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis.”Eur. J. Biochem., 263(3):605-11. (1999) (Exhibit 8).
Boney, C.M., et al., “The critical role of Shc in insulin-like growth factor-I-mediated mitogenesis and differentiation in 3T3-L1 preadipocytes.”Mol. Endocrinol., 14(6):805-13. (2000) (Exhibit 9).
Boylan, J.M., et al., “Uncoupling of hepatic, epidermal growth factor-mediated mitogen-activated protein kinase activation in the fetal rat.”J. Biol. Chem., 273(6):3784-90. (1998) (Exhibit 10).
Brown, N.S., et al., “Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer.”Breast Cancer Res., 3(5):323-7. (2001) (Exhibit 11).
Buday, L. et al., “Epidermal growth factor regulates p2lras through the formation of a complex of receptor, Grb2 adaptor protein, and Sos nucleotide exchange factor.”Cell, 73(3):611-20. (1993) (Exhibit 12).
Buday, L., et al., “Downregulation of the Ras activation pathway by MAP kinase phosphorylation of Sos.”Oncogene, 11(7):1327-31. (1995) (Exhibit 13).
Bundred, N.J., et al., “Studies of epidermal growth factor receptor inhibition in breast cancer.”Endocr. Relat. Cancer8(3):183-9. (2001) (Exhibit 14).
Carraway, K.L., et al., “A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling.”Cell, 78(1):5-8. (1994) (Exhibit 15).
Carraway, K.L., et al., “Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2
eu and erbB3.”J. Biol. Chem., 270(13):711 1-6. (1995) (Exhibit 16).
Chen, D., et al., “SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways.”J. Biol. Chem., 271(11):6328-32. (1996) (Exhibit 17).
Clark, J.W., et al., “Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer cell lines and proteins important in the Ras signaling pathway.”Int. J. Cancer, 65(2):186-91 (1996) (Exhibit 18).
Cohen, G.B., et al., “Modular binding domains in signal transduction proteins.”Cell, 80(2):237-48 (1995) (Exhibit 19).
Collins, L.R., et al., “Bifurcation of cell migratory ad proliferative signaling by adapter protein Shc.”J. Cell. Biol., 147(7
Davol Pamela A.
Frackelton, Jr. A. Raymond
Gussow Anne M.
Hamilton Brook Smith & Reynolds P.C.
Roger Williams Hospital
LandOfFree
Shc protein-related methods and compositions for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Shc protein-related methods and compositions for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Shc protein-related methods and compositions for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2649691